Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 14/20 | 0.47 |
| ▸ | RAB9A | P51151 | 14/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 13/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.44 |
| ▸ | RELA | Q04206 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140467 | 0.85 | DYRK1A (0.51) | PIK3CGDYRK1AITK | |
| SCHEMBL144539 | 0.83 | MAPT (0.55) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL138887 | 0.83 | RAB9A (0.52) | PIK3CGNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL142882 | 0.76 | ITK (0.65) | ITK | |
| SCHEMBL142881 | 0.76 | ITK (0.65) | ITK | |
| SCHEMBL138886 | 0.71 | LCK (0.46) | PIK3CGNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3112891 | 0.70 | NPC1 (0.78) | PIK3CGNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL30073965 | 0.70 | NPC1 (0.78) | PIK3CGNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL29598169 | 0.69 | NPC1 (0.56) | PIK3CGNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL29235724 | 0.69 | NPC1 (0.56) | PIK3CGNPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058984-A1 | PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS | DTYMK, ITK, DCK | PIK3CG 308/4885NPC1 2786/4885RAB9A 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.